Incretion is a process of internal secretion of hormone through endocrine glands. These hormones control the major internal body functions such as digestive activities and movement. Sometimes these hormones are not secreted in an appropriate amount to control internal body functions. When such situation arises, a patient is advised for intake of incretion drugs. These incretion drugs stimulate secretion of various endocrine hormones as per the body requirement.
Prescription of an incretion drug varies as per the disease condition. A patient may suffer from endocrinal disorders such as diabetes; thyroid and infertility for which incretion drugs could be prescribed. In addition, these drugs could also be prescribed when pituitary and adrenal glands fail to secrete hormones in appropriate amount. Various incretion drugs include Orinase (tolbutamide), Amaryl (gimepiride), Glucotrol XL (glipizide), Glucotrol (glipizide), Micronase (glyburide), DiaBeta (glyburide), Glynase PresTab (glyburide, micronized), Prandin (repaglinide) and Starlix (nateglinide). Other incretion drugs are Januvia, Onglyza, Tradjenta, Glucovance, Metaglip, ActoPlus Met, Avandamet, Duetact, Avandryl, PrandiMet, Janumet, PrandiMet, ActoPlus Met XR and Kombiglyze XR.
Rise in geriatric population globally would augment the growth of these drugs market. In addition, rise in complexities of pregnancy such as overt diabetes, infertility, hormonal imbalance would also boost the growth of this market. Moreover, rise in obese population worldwide is anticipated to further trigger the demand for these medicines. According to the Department of Health Statistics and Information Systems at WHO, around 12% of the total world population suffers every year from obesity. These incretion drugs have proven to be beneficial for treatment of obesity.
Some of the major players in this market are Abbott Laboratories, Bayer Healthcare, Novartis, Eli Lilly, and Bristol-Myers Squibb amongst other significant players.
Interested in this report?
Get a FREE Brochure now!